Patents Assigned to Bioscience, Inc.
  • Spatially Encoded Biological Assays
    Publication number: 20200208206
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: Prognosys Biosciences, Inc.
    Inventor: Mark S. CHEE
  • METHODS FOR PRODUCING RECOMBINANT PROTEINS
    Publication number: 20200207812
    Abstract: Provided herein are methods of producing a recombinant protein that include: providing a bacterium including a nucleic acid encoding a recombinant protein; and culturing the bacterium in a liquid culture medium including about 0.3 mM to about 300 mM Mg2+ under conditions sufficient for the production and release of the recombinant protein into the culture medium.
    Type: Application
    Filed: December 5, 2019
    Publication date: July 2, 2020
    Applicant: Coherus BioSciences, Inc.
    Inventor: Robert Neal Williams
  • Spatially Encoded Biological Assays
    Publication number: 20200208205
    Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: Prognosys Biosciences, Inc.
    Inventor: Mark S. CHEE
  • Exosome transfer of nucleic acids to cells
    Patent number: 10695443
    Abstract: Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Codiak BioSciences, Inc.
    Inventors: Jan Lötvall, Hadi Valadi
  • Methods for predicting post-operative recurrence of Crohn's disease
    Patent number: 10697961
    Abstract: The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 30, 2020
    Assignees: Prometheus Biosciences, Inc., Katholieke Universiteit Leuven
    Inventors: Steven Lockton, Marc Ferrante, Severine Vermiere, Sharat Singh
  • Cell culture incubators with integrated cell manipulation systems
    Patent number: 10696937
    Abstract: Aspects of the invention relate to automated cell culture incubators. In some embodiments, automated cell culture incubators comprise an integrated manipulation having one or more cell scrapers.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: June 30, 2020
    Assignee: Thrive Bioscience, Inc.
    Inventor: Alan Blanchard
  • IL17A Antibodies and Antagonists for Veterinary Use
    Publication number: 20200199216
    Abstract: Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.
    Type: Application
    Filed: June 18, 2018
    Publication date: June 25, 2020
    Applicant: Kindred Biosciences, Inc.
    Inventors: Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan
  • COMPOSITION AND METHOD FOR SEGREGATING EXTRACELLULAR DNA IN BLOOD
    Publication number: 20200196594
    Abstract: A composition and method suitable for separating and segregating extracellular DNA in a cell-containing sample, in particular, a blood sample is described. The composition comprising a thixotropic barrier gel and a stabilizing agent in aqueous solution at a concentration of at least 400 mM is capable of establishing and maintaining separation between intracellular and extracellular DNA in blood over time by means of physical barrier wherein when the composition is mixed with whole blood and centrifuged, plasma is separated from the packed cell layer by the thixotropic barrier gel and the blood cells are separated away from the plasma.
    Type: Application
    Filed: December 23, 2019
    Publication date: June 25, 2020
    Applicant: deltaDNA Biosciences Inc.
    Inventors: Hyman Chaim Birnboim, Michelle Bamji-Mirza
  • Iterative feature selection methods
    Patent number: 10692005
    Abstract: Feature selection methods and processes that facilitate reduction of model components available for iterative modeling. It has been discovered that methods of eliminating model components that do not meaningfully contribute to a solution can be preliminarily discovered and discarded, thereby dramatically decreasing computational requirements in iterative programming techniques. This development unlocks the ability of iterative modeling to be used to solve complex problems that, in the past, would have required computation time on orders of magnitude too great to be useful.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 23, 2020
    Assignee: Liquid Biosciences, Inc.
    Inventor: Patrick Lilley
  • Sphingoid compounds for prophylaxis and/or therapy of a viral infection
    Patent number: 10688065
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 23, 2020
    Assignee: Harbins Ruhr Bioscience, Inc.
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Real time electronic cell sensing systems and applications for cell-based assays
    Patent number: 10690677
    Abstract: Methods for identifying compounds that modulate cellular responses stimulated by IgE, which include providing an impedance-based system that monitors cell-substrate impedance of cells on a substrate; introducing cells to the substrate of the system; adding at least one test compound and IgE to the cells, wherein the at least one test compound is suspected of modulating cell responses stimulated by the IgE; adding an antigen to the cells; monitoring the cell-substrate impedance of cells on the substrate; and analyzing the cell-substrate impedance to evaluate whether the at least one test compound alters a cellular response to stimulation with the IgE.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 23, 2020
    Assignee: ACEA Biosciences, Inc.
    Inventors: Xiao Xu, Yama A. Abassi, Xiaobo Wang, Jiangbo Gan
  • HPV particles and uses thereof
    Patent number: 10688172
    Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 23, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Aura Biosciences, Inc.
    Inventors: Pierre L. Coursaget, Antoine A. Touźe, Maxime J. J. Fleury, Nicolas Combelas, Elisabet de los Pinos
  • Optimized anti-TL1A antibodies
    Patent number: 10689439
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: June 23, 2020
    Assignee: Prometheus Biosciences, Inc.
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
  • Stable aqueous formulations of adalimumab
    Patent number: 10688183
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 23, 2020
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
    Patent number: 10689449
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 23, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORS
    Publication number: 20200188529
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 18, 2020
    Applicants: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
  • METHODS FOR REDUCING DNA-INDUCED CYTOTOXICITY AND ENHANCING GENE EDITING IN PRIMARY CELLS
    Publication number: 20200190541
    Abstract: An obstacle in the use of many primary cells is the significant cytotoxicity observed following transfection with circular or linearized DNA. Methods are provided for improving the survival of any primary cell following transfection with circular or linearized DNA. The methods of the invention are also useful for improving gene editing by endonucleases in DNA-transfected primary cells, and for improving the efficiency of targeted insertion of exogenous sequences into the genome of DNA-transfected primary cells.
    Type: Application
    Filed: April 30, 2018
    Publication date: June 18, 2020
    Applicant: Precision BioSciences, Inc.
    Inventor: Mark Johnson
  • Compositions and methods for treatment and prevention of pyrexia in horses
    Patent number: 10682337
    Abstract: Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 16, 2020
    Assignee: Kindred Biosciences, Inc.
    Inventor: Emily Sundman
  • PHARMACEUTICAL FORMULATIONS AND THEIR USE
    Publication number: 20200179319
    Abstract: Disclosed herein are pharmaceutical compositions, comprising a therapeutically effective amount of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or a pharmaceutically acceptable salt thereof, and at least one protective agent, and uses thereof.
    Type: Application
    Filed: August 4, 2017
    Publication date: June 11, 2020
    Applicant: Signum Biosciences, Inc.
    Inventors: Thomas John Willi, John Frederick Lang, Laura Jean Weston
  • SYSTEMS AND METHODS FOR CELL DISSOCIATION
    Publication number: 20200182774
    Abstract: A system for dissociating cells from a cell culture vessel. The system comprises an imaging system configured to image a plurality of cells in a cell culture vessel being dissociated from at least one surface of the cell culture vessel by at least one cell dissociation agent; and at least one controller coupled to the imaging system and configured to: control the imaging system to capture a sequence of images of at least some cells in the plurality of cells during dissociation; and identify when to neutralize the at least one cell dissociation agent using the sequence of images.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 11, 2020
    Applicant: Thrive Bioscience, Inc.
    Inventors: Kam Lin Wong, Melanie Scully